Agios to Present at the 2024 Cantor Global Healthcare Conference on September 18, 2024
Agios Pharmaceuticals (Nasdaq: AGIO), a leader in cellular metabolism and PK activation therapies for rare diseases, has announced its participation in the 2024 Cantor Global Healthcare Conference. The company is scheduled to present on Wednesday, September 18, 2024, at 10:20 a.m. ET.
Investors and interested parties can access a live webcast of the presentation through the 'Events & Presentations' section of Agios' website at www.agios.com. For those unable to attend the live event, a replay of the webcast will be available on the company's website for at least two weeks following the presentation, ensuring widespread access to the information shared during the conference.
Agios Pharmaceuticals (Nasdaq: AGIO), un leader nelle terapie contro le malattie rare basate sul metabolismo cellulare e sull'attivazione della PK, ha annunciato la sua partecipazione alla Conferenza Globale Sanitaria Cantor 2024. L'azienda è programmata per presentare mercoledì 18 settembre 2024, alle 10:20 ET.
Investitori e parti interessate possono accedere a un webcast dal vivo della presentazione attraverso la sezione 'Eventi e Presentazioni' del sito web di Agios all'indirizzo www.agios.com. Per coloro che non possono partecipare all'evento dal vivo, una riproduzione del webcast sarà disponibile sul sito dell'azienda per almeno due settimane dopo la presentazione, garantendo un ampio accesso alle informazioni condivise durante la conferenza.
Agios Pharmaceuticals (Nasdaq: AGIO), un líder en terapias de metabolismo celular y activación de PK para enfermedades raras, ha anunciado su participación en la Conferencia Global de Salud Cantor 2024. La empresa tiene programado presentar el miércoles 18 de septiembre de 2024, a las 10:20 a.m. ET.
Los inversores y partes interesadas pueden acceder a un webcast en vivo de la presentación a través de la sección 'Eventos y Presentaciones' del sitio web de Agios en www.agios.com. Para aquellos que no puedan asistir al evento en vivo, habrá una repetición del webcast disponible en el sitio web de la empresa durante al menos dos semanas después de la presentación, asegurando un amplio acceso a la información compartida durante la conferencia.
Agios Pharmaceuticals (Nasdaq: AGIO)는 희귀 질환에 대한 세포 대사 및 PK 활성화 요법의 선두주자로서 2024 칸토르 글로벌 헬스케어 컨퍼런스에 참가한다고 발표했습니다. 회사는 2024년 9월 18일 수요일 오전 10시 20분 ET에 발표할 예정입니다.
투자자와 이해관계자는 Agios 웹사이트의 '이벤트 및 발표' 섹션을 통해 발표의 실시간 웹캐스트에 접근할 수 있습니다. 생중계 행사에 참석할 수 없는 분들을 위해 발표 이후 최소 2주간 회사 웹사이트에 웹캐스트 재방송이 제공되어 회의 중 공유된 정보에 널리 접근할 수 있도록 보장합니다.
Agios Pharmaceuticals (Nasdaq: AGIO), un leader dans les thérapies sur le métabolisme cellulaire et l'activation de la PK pour les maladies rares, a annoncé sa participation à la Conférence Mondiale sur les Soins de Santé Cantor 2024. L'entreprise est prévue pour faire une présentation le mercredi 18 septembre 2024, à 10h20 ET.
Les investisseurs et les parties intéressées peuvent accéder à un webcast en direct de la présentation via la section 'Événements et Présentations' du site Web d'Agios à l'adresse www.agios.com. Pour ceux qui ne peuvent pas assister à l'événement en direct, une rediffusion du webcast sera disponible sur le site de l'entreprise pendant au moins deux semaines après la présentation, garantissant un large accès aux informations partagées lors de la conférence.
Agios Pharmaceuticals (Nasdaq: AGIO), ein führendes Unternehmen in der Zellstoffwechsel- und PK-Aktivierungstherapie für seltene Krankheiten, hat seine Teilnahme an der 2024 Cantor Global Healthcare Conference bekannt gegeben. Das Unternehmen wird am Mittwoch, den 18. September 2024, um 10:20 Uhr ET präsentieren.
Investoren und Interessierte können über den Bereich 'Veranstaltungen und Präsentationen' auf der Website von Agios unter www.agios.com auf ein Live- Webcast der Präsentation zugreifen. Für diejenigen, die an der Live-Veranstaltung nicht teilnehmen können, wird eine Wiederholung des Webcasts mindestens zwei Wochen nach der Präsentation auf der Unternehmenswebsite verfügbar sein, um einen breiten Zugang zu den während der Konferenz geteilten Informationen zu gewährleisten.
- None.
- None.
CAMBRIDGE, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that the company is scheduled to present at the 2024 Cantor Global Healthcare Conference on Wednesday, September 18, 2024, at 10:20 a.m. ET.
A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors section of the company's website at www.agios.com. A replay of the webcast will be archived on the company’s website for at least two weeks following the presentation.
About Agios
Agios is the pioneering leader in PK activation and is dedicated to developing and delivering transformative therapies for patients living with rare diseases. In the U.S., Agios markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for this rare, lifelong, debilitating hemolytic anemia. Building on the company's deep scientific expertise in classical hematology and leadership in the field of cellular metabolism and rare hematologic diseases, Agios is advancing a robust clinical pipeline of investigational medicines with programs in alpha- and beta-thalassemia, sickle cell disease, pediatric PK deficiency, MDS-associated anemia and phenylketonuria (PKU). In addition to its clinical pipeline, Agios is advancing a preclinical TMPRSS6 siRNA as a potential treatment for polycythemia vera. For more information, please visit the company’s website at www.agios.com.
Contacts:
Investor Contact
Chris Taylor, VP, Investor Relations and Corporate Communications
Agios Pharmaceuticals
IR@agios.com
Media Contact
Dan Budwick
1AB
dan@1abmedia.com
FAQ
When is Agios Pharmaceuticals (AGIO) presenting at the 2024 Cantor Global Healthcare Conference?
How can I watch Agios Pharmaceuticals' (AGIO) presentation at the 2024 Cantor Global Healthcare Conference?
Will there be a replay available of Agios Pharmaceuticals' (AGIO) presentation at the 2024 Cantor conference?
What is Agios Pharmaceuticals' (AGIO) focus in the healthcare industry?
